Disease |
Disease |
Method |
Sample |
Expression pattern |
Dysfunction type |
Description |
PMID |
Source |
prostate cancer |
microarray, qPCR, Western blot, knockdown, Luciferase reporter assay etc. |
prostate tissue, cell lines (Du145-derived, RWPE-derived, LNCAP-derived, PC3-derived etc.) |
up-regulated |
regulation |
PCAT1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. |
24473064 |
LncRNADisease Lnc2Cancer
|
prostate cancer |
microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. |
prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) |
up-regulated |
N/A |
Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. |
23728290 |
Lnc2Cancer
|
prostate cancer |
N/A |
N/A |
N/A |
regulation |
They described PCAT1,a novel PCa lincRNA on 8q24, in the locality of well-characterized PCa risk-related SNPs and the c-MYC oncogene. |
24146262 |
LncRNADisease
|
prostate cancer |
N/A |
N/A |
N/A |
expression |
Putative marker and oncogene |
24373479 |
LncRNADisease
|
prostate cancer |
N/A |
N/A |
N/A |
regulation |
The prostate cancer-associated ncRNA transcript 1 lncRNA PCAT1, SchlAP1 (second chromosome locus associated with prostate-1), and CTBP1-AS indicate cancer cell invasiveness and metastasis in prostate cancer progression. |
24531795 |
LncRNADisease
|
colorectal cancer |
qPCR etc. |
CRC tissue |
up-regulated |
N/A |
Our results showed that PCAT-1 expression in CRC tissues was significantly upregulated compared with the matched normal tissues and the overexpression of PCAT-1 was found in 64 % (62/81) of CRC. In addition, there was a significant association between PCAT-1 expression and distant metastasis. More important, CRC patients with PCAT-1 higher expression have shown significantly poorer overall survival than those with lower PCAT-1 expression. In conclusion, our results suggest that high expression of PCAT-1 is involved in CRC progression and could be a novel biomarker of poor prognosis in patient with colorectal cancer. |
23640607 |
Lnc2Cancer
|
esophageal squamous cell carcinoma |
qPCR etc. |
ESCC tissue |
up-regulated |
interaction |
The expression of PCAT-1 was significantly higher in human ESCC compared with the adjacent noncancerous tissues (70.8 %, p < 0.01), and the high level of PCAT-1 expression was significantly correlated with invasion of the tumor (p = 0.024), advanced clinical stage (p = 0.003), lymph node metastasis (p = 0.032), and poor prognosis. |
25731728 |
Lnc2Cancer
|
bladder cancer |
qPCR etc. |
bladder cancer tissue, cell lines (T24, 5637 etc.) |
up-regulated |
expression |
In this study, we found that PCAT-1 was up-regulated in bladder cancer compared to paired normal urothelium.PCAT-1 plays oncogenic roles. |
25934337 |
Lnc2Cancer
|
prostate cancer |
qPCR, Luciferase reporter assay, knockdown etc. |
cell lines (LNCaP) |
up-regulated |
regulation |
We show that PCAT-1 promotes prostate cell proliferation and that this phenotype is mediated through up-regulation of the cMyc protein (encoded by the MYC gene). Antagonism of cMyc is able to reverse PCAT-1mediated cell proliferation. We show that PCAT-1 regulates cMyc post-transcriptionally through the MYC 3' untranslated region (UTR). Further, we find a protetcive effetc of PCAT-1 on cMyc by interfering with the regulation of MYC by miR-34a. |
25425964 |
Lnc2Cancer
|
non-small cell lung cancer |
quantitative real-time PCR (QRT-PCR), suppression |
non-small cell lung cancer cells |
up-regulated |
expression |
PCAT-1 suppression using PCAT-1 small hairpin RNA (shRNA) with A549 cells inhibited cell proliferation, migration and invasion, while over-expression of PCAT-1 by synthetic plasmid vectors was shown to promote cell proliferation, migration and invasion. Our data suggested that PCAT-1 could play an oncogenic role in NSCLC progression. Silencing PCAT-1 is a potential novel therapeutic approach for lung cancer. |
26770456 |
|
prostate cancer |
RNA-seq, qPCR, Western blot etc. |
prostate cancer tissue, cell lines (VCaP, LNCaP) |
up-regulated |
expression |
PCAT1 is markedly overexpressed in a subset of prostate cancers, particularly metastases, and may contribute to cell proliferation in these tumors. |
21804560 |
LncRNADisease Lnc2Cancer
|
hepatocelluar carcinoma |
the reverse transcription-quantitative polymerase chain reaction |
HCC tissue samples and HepG2 and Bel‑7402 cell lines |
up-regulated |
N/A |
Overexpression of PCAT‑1 induced synthetic plasmid vectors |
27035680 |
|
|